Yen-Wah Lee

Title: Innovations and Contributions of Inventor Yen-Wah Lee

Introduction

Yen-Wah Lee is a notable inventor based in Gaithersburg, MD (US). He has made significant contributions to the field of biomedical research, particularly in the area of interleukin-23 (IL23)-mediated diseases. With a total of six patents to his name, Lee's work has the potential to impact the treatment of conditions such as Crohn's disease.

Latest Patents

One of Yen-Wah Lee's latest patents is focused on the use of CCL20 as a predictor of clinical response to IL23-antagonists. This invention relates to utilizing the Chemokine (C-C motif) ligand 20 (CCL20) as a biomarker to identify patients suffering from IL23-mediated diseases who are responsive to anti-IL23 treatment. The patent outlines how levels of CCL20 can determine patient eligibility for treatment, guide treatment decisions, and predict treatment outcomes. Another significant patent involves the prediction of clinical response to IL23-antagonists using IL23 pathway biomarkers, including IL22 and lipocalin-2 (LCN2). This invention also aims to stratify patients with IL23-mediated diseases based on their response to therapeutic agents.

Career Highlights

Yen-Wah Lee has worked with prominent companies in the biotechnology sector, including MedImmune Limited and Amgen Fremont Inc. His experience in these organizations has contributed to his expertise in developing innovative solutions for complex medical challenges.

Collaborations

Some of Yen-Wah Lee's notable coworkers include Meina Liang and Raffaella Faggioni. Their collaborative efforts have likely enhanced the research and development of innovative treatments in their field.

Conclusion

Yen-Wah Lee's contributions to the field of biomedical research through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in the treatment of IL23-mediated diseases.